EUVIMEDEUVIMED entdecken
Multizentrische Studie

Venetoclax plus decitabine, cytarabine, aclarubicin, and G‐ CSF in adults with newly diagnosed acute myeloid leukemia: A multicenter, retrospective study

Ying Zhang, Kun Yang, Yong Guo, Jin Rao, Feng Wang, Yunfan Yang iD, Zhongqing Zou, Kai Shen, Chunyan Liang, Hongwei Wu, Chenlu Yang, Wenjiao Tang und 12 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70239 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Ying Zhang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Leukemia, Myeloid, Acute. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, 1·3·5 project for disciplines of excellence - Clinical Research Fund, West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This multicenter, retrospective study evaluated the efficacy and safety of the venetoclax plus decitabine, cytarabine, aclarubicin, and granulocyte colony‐stimulating factor (VD‐CAG) regimen in newly diagnosed acute myeloid leukemia (ND‐AML) patients aged 18–60. The analysis included, but was not limited to, the composite complete response (CRc) rate, measurable residual disease (MRD) negativity rate, overall survival (OS), event‐free survival (EFS), and safety. A total of 107 adult patients with AML were included in the study, conducted between March 1, 2022, and December 31, 2024. The median age was 49 years (range: 18–60 years), with a male‐to‐female ratio of 44:63. The CRc rate after one cycle of the VD‐CAG regimen was 86.9% (95% CI 79–92.7; 93 of 107 patients) in the entire cohort. 73 (79%) of 93 patients who reached CRc had undetectable MRD. Grade 3 or worse adverse events included neutropenia in 107 (100%) of 107 patients, thrombocytopenia in 107 (100%), anemia in 107 (100%), febrile neutropenia in 57 (53%), pneumonia in 10 (9.3%), sepsis in five (4.7%), and tumor lysis syndrome in three (2.8%). No treatment‐related deaths occurred. With a median follow‐up of 8.8 months (range: 1–33.5 months), the median EFS and OS are not reached. The estimated 12‐month OS was 90% (95% CI 90–95) and 12‐month EFS was 79% (95% CI 69–87). The VD‐CAG regimen represents an effective induction therapy for young ND‐AML. It leads to high rates of CRc and MRD‐negative remissions, along with encouraging OS and EFS across prognostic subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Myeloid, AcuteHumansFemaleMaleAdultMiddle AgedRetrospective StudiesCytarabineDecitabineAclarubicinYoung AdultAdolescentGranulocyte Colony-Stimulating FactorBridged Bicyclo Compounds, HeterocyclicSulfonamidesNeoplasm, Residual

Stichwörter der Autor:innen

CAGacute myeloid leukemiadecitabineinduction treatmentvenetoclax

Substanzen

venetoclaxCytarabineDecitabineAclarubicinGranulocyte Colony-Stimulating FactorBridged Bicyclo Compounds, HeterocyclicSulfonamides

Autor:innen und Institutionen

  • Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Hematology, Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, China.
  • Department of Hematology and Oncology, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region, Chengdu, China.
  • Department of Hematology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
  • Department of Hematology, Dazhou Central Hospital, Dazhou, China.

ORCID-Profile: Yunfan Yang, Yuping Gong

Förderung

  • Science and Technology Department of Sichuan Province
  • 1·3·5 project for disciplines of excellence - Clinical Research Fund, West China Hospital, Sichuan University

Zitieren

APA

Zhang, Y., Yang, K., Guo, Y., Rao, J., Wang, F., Yang, Y., Zou, Z., Shen, K., Liang, C., Wu, H., Yang, C., Tang, W., Ling, Y., Du, Y., Tang, J., Wang, M., Zhang, D., Yu, X., Chen, Q., …, & Gong, Y. (2026). Venetoclax plus decitabine, cytarabine, aclarubicin, and G‐ CSF in adults with newly diagnosed acute myeloid leukemia: A multicenter, retrospective study. International Journal of Cancer. https://doi.org/10.1002/ijc.70239

Vancouver

Zhang Y, Yang K, Guo Y, Rao J, Wang F, Yang Y, et al. Venetoclax plus decitabine, cytarabine, aclarubicin, and G‐ CSF in adults with newly diagnosed acute myeloid leukemia: A multicenter, retrospective study. International Journal of Cancer. 2026. doi:10.1002/ijc.70239

BibTeX
@article{Zhang2026,
  author = {Zhang, Ying and Yang, Kun and Guo, Yong and Rao, Jin and Wang, Feng and Yang, Yunfan and Zou, Zhongqing and Shen, Kai and Liang, Chunyan and Wu, Hongwei and Yang, Chenlu and Tang, Wenjiao and Ling, Yantao and Du, Yiwen and Tang, Jirui and Wang, Mei and Zhang, Duanzhong and Yu, Xiaoling and Chen, Qi and Xiong, Yanqiu and He, Xu and Zhan, Yuchen and Ma, Hongbin and Gong, Yuping},
  title = {Venetoclax plus decitabine, cytarabine, aclarubicin, and G‐ CSF in adults with newly diagnosed acute myeloid leukemia: A multicenter, retrospective study},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70239}
}
Kostenlos starten →